Spearhead Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Spearhead Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,929	Closed	-$302K	–	194
2021 Q4	$302K	Buy	12,929 +300	+2%	+$6.03K	0.04%	146
2021 Q3	$210K	Sell	12,629 -122	-1%	-$2.35K	0.03%	180
2021 Q2	$311K	Buy	+12,751	New	+$288K	0.04%	175
2021 Q1	–	Sell	-5,547	Closed	-$297K	–	186
2020 Q4	$297K	Buy	5,547 +164	+3%	+$8.14K	0.05%	140
2020 Q3	$222K	Buy	5,383 +364	+7%	+$15.7K	0.04%	172
2020 Q2	$243K	Buy	+5,019	New	+$241K	0.05%	133

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Spearhead Capital Advisors's ACAD Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 12,929 shares — an estimated $302K sold.

Spearhead Capital Advisors first reported a position in ACAD in Q2 2020 and held it in 6 quarters. The position peaked at $311K in Q2 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

Spearhead Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Spearhead Capital Advisors sold 12,929 Acadia Pharmaceuticals shares in Q1 2022, an estimated $302K.
Spearhead Capital Advisors first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Spearhead Capital Advisors's Acadia Pharmaceuticals position peaked at $311K in Q2 2021.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.